Last reviewed · How we verify
ZD1839 (Gefitinib)
ZD1839 (Gefitinib) is a small molecule that inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase.
ZD1839 (Gefitinib) is a small molecule that inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase. Used for Non-small cell lung cancer, EGFR mutation positive, Locally advanced or metastatic non-small cell lung cancer.
At a glance
| Generic name | ZD1839 (Gefitinib) |
|---|---|
| Also known as | Iressa |
| Sponsor | AstraZeneca |
| Drug class | EGFR tyrosine kinase inhibitor |
| Target | EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This inhibition prevents the activation of downstream signaling pathways that promote cell proliferation and survival, ultimately leading to the death of cancer cells. ZD1839 has been shown to be effective in treating non-small cell lung cancer, particularly in patients with specific EGFR mutations.
Approved indications
- Non-small cell lung cancer, EGFR mutation positive
- Locally advanced or metastatic non-small cell lung cancer
Common side effects
- Diarrhea
- Rash
- Nausea
- Vomiting
- Fatigue
- Anorexia
- Dyspnea
- Cough
- Headache
- Dizziness
Key clinical trials
- A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma (PHASE2)
- Therapy for Advanced NSCLC With EGFR 19delins Mutation (EARLY_PHASE1)
- A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
- Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone (PHASE2)
- Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases
- A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (PHASE3)
- Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC (PHASE1)
- A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ZD1839 (Gefitinib) CI brief — competitive landscape report
- ZD1839 (Gefitinib) updates RSS · CI watch RSS
- AstraZeneca portfolio CI